The DKK1 Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed for loss-of-function analysis of human DKK1. Generated via CRISPR/Cas9-mediated gene disruption in the UM-UC-3 bladder carcinoma epithelial cell line, this mixed population avoids single-cell clonal biases and better reflects cellular heterogeneity. DKK1 encodes Dickkopf-related protein 1, a secreted Wnt antagonist implicated in cancer biology, stem cell maintenance, and development. These cells enable investigation of Wnt/??-catenin pathway dynamics without confounding DKK1-mediated ligand inhibition.
The UM-UC-3 parental line originates from a human bladder transitional cell carcinoma and serves as a widely accepted model for invasive bladder cancer. These epithelial cells display molecular hallmarks of high-grade urothelial carcinoma, including altered Wnt signaling, and are utilized in tumorigenesis, metastasis, and drug response studies. The engineered DKK1 knockout in this genetic background allows direct functional interrogation of DKK1 in malignant phenotypes.
DKK1 is a secreted inhibitor of canonical Wnt/??-catenin signaling. It binds LRP5/6 co-receptors together with Kremen1/2 to promote endocytosis of the Wnt receptor complex, thereby preventing ligand binding and downstream signal propagation. This results in reduced Dishevelled activation, enhanced ??-catenin degradation via the AXIN/GSK3?? complex, and suppressed TCF/LEF-mediated transcription of targets such as MYC, CCND1, and AXIN2. DKK1 expression is controlled by upstream regulators including Wnt3a, the ??-catenin/TCF complex, TP53, TGF-??, and BMP4, placing it at a key negative feedback point in the pathway.
In UM-UC-3 cells, DKK1 disruption is expected to relieve Wnt pathway inhibition, leading to ??-catenin stabilization and increased TCF/LEF activity, mimicking the hyperactive Wnt states found in aggressive bladder, colorectal, breast, and prostate cancers. This polyclonal model thus enables dissection of DKK1??s tumor-suppressive or oncogenic roles in a context where Wnt dysregulation drives proliferation, EMT, and drug resistance.
These cells support diverse assays, including TOP/FOP Flash luciferase reporter assays for TCF/LEF activity, RNA-seq for global transcriptomics, western blotting and immunofluorescence for ??-catenin, RT-qPCR for Wnt targets (MYC, CCND1, AXIN2), and functional tests for migration, invasion, and apoptosis. Co-immunoprecipitation with LRP6 or Kremen can confirm altered receptor interactions. For additional information or custom requests, please contact Ascent Research.
